Cetuximab rechallenge (mCRC RAS/BRAF-WT, post-1L EGFRi response, ctDNA-guided 3L+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CETUXIMAB |
|---|
| ID | REG-CETUXIMAB-RECHALLENGE |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-CHRONOS-SARTORE-BIANCHI-2022 SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
CRICKET (Cremolini 2019, JAMA Oncol) and CHRONOS (Sartore-Bianchi 2022, Nat Med) established cetuximab rechallenge as a 3L+ option in mCRC patients who previously responded to a 1L EGFRi-containing regimen (FOLFOX-cetuximab or FOLFIRI-cetuximab), then progressed, then received an EGFRi-free 2L. ctDNA-guided selection (RAS-WT clearance on liquid biopsy at time of rechallenge) substantially improves response rate (CHRONOS: ORR ~30% in ctDNA-RAS-WT vs ~0% in mutant). Pre-rechallenge ctDNA RAS/BRAF testing strongly recommended.
Used By
Indication
IND-CRC-METASTATIC-3L-RECHALLENGE-EGFRI- IND-CRC-METASTATIC-3L-RECHALLENGE-EGFRI